Research map: Rebalancing innovation, affordability, and access for orphan drugs in the European Union

Back to the article

Papers in this map

  1. Drug repurposing: progress, challenges and recommendations · Sudeep P. Pushpakom · 2018 · 4872 citations · Cited by this paper
  2. Estimating the Potential Burden of Clinically Significant Hantavirus Cases in Argentina · 2026 · Related
  3. Targeted therapy in patients with PIK3CA-related overgrowth syndrome · Quitterie Venot · 2018 · 598 citations · Cited by this paper
  4. GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin · 2026 · Related
  5. Pharmaceutical Price Controls and Entry Strategies · Margaret Kyle · 2007 · 311 citations · Cited by this paper
  6. Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease · 2026 · Related
  7. Advance Market Commitments: Insights from Theory and Experience · Michael R. Kremer · 2020 · 92 citations · Cited by this paper
  8. Ending the Chronic Liver Disease Public Health Threat: Systemic Challenges Through the Patient Lens · 2026 · Related
  9. Comparing access to orphan medicinal products in Europe · Bernarda Zamora · 2019 · 90 citations · Cited by this paper
  10. Preparing Europe for Recurrent Autochthonous Dengue Transmission: Public Health Implications and Preparedness Priorities · 2026 · Related
  11. The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review · Emily Leckenby · 2021 · 70 citations · Cited by this paper
  12. From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid Therapy · 2026 · Related
  13. Can Financial Engineering Cure Cancer? · David E. Fagnan · 2013 · 56 citations · Cited by this paper
  14. Nordic AI-Health: a unique opportunity for discovery and clinical impact · 2026 · Related
  15. Orphan drug pricing may warrant a competition law investigation · Jonathan C. P. Roos · 2010 · 53 citations · Cited by this paper
  16. Safety of the Dengue Vaccine TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain · 2026 · Related
  17. Designing Advance Market Commitments for New Vaccines · Michael R. Kremer · 2022 · 51 citations · Cited by this paper
  18. Assessing Europe's policy readiness to confront the MASLD/MASH public health threat · 2026 · Related
  19. The Innovative Medicines Initiative −10 Years of Public-Private Collaboration · Hugh Laverty · 2019 · 44 citations · Cited by this paper
  20. Global insight into rare disease and orphan drug definitions: a systematic literature review · Ghada Abo-Zaid · 2025 · 20 citations · Cited by this paper
  21. Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement · Hans‐Georg Eichler · 2023 · 17 citations · Cited by this paper
  22. Economic considerations in cooperative research and development agreements (CRADA): The case of Taxol, NIH, and technology transfer · Thomas A. Hemphill · 2005 · 14 citations · Cited by this paper
  23. Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation · Sanae Akodad · 2026 · 13 citations · Cited by this paper
  24. Reliable business case for repurposing of existing medicines requires key changes in government policies · Samuel J de Visser · 2024 · 9 citations · Cited by this paper
  25. Early access disparities in innovative therapies across the US, EU, China, and Japan · Sanae Akodad · 2025 · 6 citations · Cited by this paper
  26. The Innovative Health Initiative public–private partnership: a catalyst for big data-driven health research and innovation · Elisabetta Vaudano · 2025 · 5 citations · Cited by this paper
  27. A novel approach to boost drug development in paediatric oncology · Sam Daems · 2023 · 4 citations · Cited by this paper
  28. Making CAR T-cell therapies more affordable · Kathryn Senior · 2024 · 4 citations · Cited by this paper
  29. The Economics of Drug Development: A Comparison between Orphan and Non-orphan Drugs · Gomase VS · 2025 · 3 citations · Cited by this paper
  30. Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes · Baptiste Haon · 2026 · 1 citation · Cited by this paper
  31. Strategic Drivers Behind Early Withdrawal of Orphan Designations in the EU: A Retrospective Analysis (2000–2024) · L. I. Bouwman · 2025 · 1 citation · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)